Shots:
- The PHYOX 3 OLE study involves assessing of nedosiran in participants aged ≥6yrs. with PH1 or PH2 who have participated in any previous PHYOX clinical development program trial as well as their siblings aged 6-18yrs. with PH
- All participants regardless of PH subtype, achieved normal or near-normal Uox excretion @day180, 92% participants (100% & 67% with PH1 & PH2) achieved normal Uox excretion at one or more visits, 62% participants (70% & 33% with PH1 & PH2) demonstrated normalized Uox excretions on at least three consecutive visits, maximum reduction in Uox excretion (70.9%)
- Nedosiran is an investigational candidate in development for the treatment of all three known types of PH – PH1, PH2, and PH3, act by inhibiting the LDH enzyme
Click here to read full press release/ article | Ref: Dicerna | Image: PRNewswire
The post Dicerna Presents New Interim Data of PHYOX 3 OLE Study Evaluating Nedosiran for Primary Hyperoxaluria at ASN Week 2020 first appeared on PharmaShots.
